Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 97

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 97
---
 and their respective management teams. 23 RISK FACTORS The following risk factors will apply to business and operations of NLS following the Closing. NLS will be faced with a market environment that cannot be predicted and that involves significant risks, many of which will be beyond its control. You should carefully consider the following risk factors in addition to the other information included in this proxy statement/prospectus before deciding how to vote your NLS Common Shares. You should also read and consider the risks associated with the business of NLS because these risks may also affect the combined company. Please see the section entitled “Where You Can Find More Information” in this proxy statement/prospectus. Risk Factors Summary The following is a summary of some of the risks and uncertainties that could materially adversely affect NLS’s business, financial condition and results of operationsfollowing the Closing. You should read this summary together with the more detailed description of each risk factor contained below: •NLS may fail to comply with data protection legislation or appropriate practices. •NLS is a Swiss stock corporation. The rights of its shareholders may be different from the rights of shareholders in companies governed by the laws of U.S. jurisdictions. •The registration of share capital increases or decreases in the commercial register may be blocked and the shareholders’ resolutions regarding the ordinary or conditional share capital increases or the introduction of a capital band may be challenged. •The NLS Common Shares are not listed in Switzerland, our home jurisdiction. As a result, the Swiss takeover regime does not apply. •U.S. shareholders may not be able to obtain judgments or enforce civil liabilities against NLS or its executive management or the NLS Board. •NLS’s status as a Swiss stock corporation means that its shareholders enjoy certain rights that may limit its flexibility to raise capital, issue dividends and otherwise manage ongoing capital needs. •Shareholders outside of the United States may not be able to exercise pre -emptiverights in future issuances of equity or other securities that are convertible into equity. •Following the closing of the Merger, NLS may lose its foreign private issuer status, which would then require it to comply with the domestic reporting requirements of the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act, and cause it to incur significant legal, accounting and other expenses. •Failure to consummate the Merger as currently contemplated or at all could adversely affect the price of NLS Common Shares or Kadimastem Ordinary Shares and the future business and financial results of NLS and Kad